

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9	MAR 22	EMBASE is now updated on a daily basis
NEWS 10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS 13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 17	MAY 11	KOREAPAT updates resume
NEWS 18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS EXPRESS	FEBRUARY 15	CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS	STN Operating Hours Plus Help Desk Availability	
NEWS LOGIN	Welcome Banner and News Items	
NEWS IPC8	For general information regarding STN implementation of IPC 8	
NEWS X25	X.25 communication option no longer available after June 2006	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * *

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:43:37 ON 30 MAY 2006

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 13:43:46 ON 30 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 May 2006 VOL 144 ISS 23
FILE LAST UPDATED: 29 May 2006 (20060529/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s (huntingtin interacting) or HIP1
      1115 HUNTINGTIN
        83 HUNTINGTINS
      1131 HUNTINGTIN
          (HUNTINGTIN OR HUNTINGTINS)
      80906 INTERACTING
        133 HUNTINGTIN INTERACTING
          (HUNTINGTIN(W) INTERACTING)
        136 HIP1
L1      217 (HUNTINGTIN INTERACTING) OR HIP1
```

```
=> s antibod?
L2      462031 ANTIBOD?
```

```
=> s autoantibod?
L3      18650 AUTOANTIBOD?
```

```
=> s 12 or 13
L4      464482 L2 OR L3
```

```
=> s serum or sera or blood or urine
```

549523 SERUM
 16762 SERUMS
 46396 SERA
 9 SERAS
 573992 SERUM
 (SERUM OR SERUMS OR SERA OR SERAS)
 46396 SERA
 9 SERAS
 46402 SERA
 (SERA OR SERAS)
 1243345 BLOOD
 1218 BLOODS
 1243478 BLOOD
 (BLOOD OR BLOODS)
 210455 URINE
 4453 URINES
 210883 URINE
 (URINE OR URINES)
 L5 1605105 SERUM OR SERA OR BLOOD OR URINE

=> s 15 (S) 14
 L6 75911 L5 (S) L4

=> s 14 (S) 15
 L7 75911 L4 (S) L5

=> s 14 (2W) 15
 L8 13791 L4 (2W) L5

=> s 18 and 11
 L9 0 L8 AND L1

=> s 15 (2W)
 MISSING TERM AFTER L5 (2W)
 Operators must be followed by a search term, L-number, or query name.

=> s 16 and 14
 L10 75911 L6 AND L4

=> s 16 and 11
 L11 5 L6 AND L1

=> d ibib 1-5

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:104603 CAPLUS
 DOCUMENT NUMBER: 144:169114
 TITLE: Analysis of gene expression profiles in urine and
 blood in early diagnosis of bladder cancer
 INVENTOR(S): Guilford, Parry, John; Kerr, Natalie, Jane; Pollock,
 Robert
 PATENT ASSIGNEE(S): Pacific Edge Biotechnology Ltd., N. Z.; Farmer,
 Charles, Davis, Jr.
 SOURCE: PCT Int. Appl., 123 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012522	A1	20060202	WO 2005-US26055	20050722
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: NZ 2004-534289 A 20040723
 NZ 2005-539219 A 20050404
 US 2005-692619P P 20050620

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:430537 CAPLUS

DOCUMENT NUMBER: 143:94728

TITLE: **Serum antibodies to
 Huntingtin interacting protein-1: A
 new blood test for prostate cancer**

AUTHOR(S): Bradley, Sarah V.; Oravec-Wilson, Katherine I.;
 Bougeard, Gaelle; Mizukami, Ikuko; Li, Lina; Munaco,
 Anthony J.; Sreekumar, Arun; Corradetti, Michael N.;
 Chinnaiyan, Arul M.; Sanda, Martin G.; Ross, Theodora
 S.

CORPORATE SOURCE: Department of Internal Medicine, University of
 Michigan Medical School, Ann Arbor, MI, USA

SOURCE: Cancer Research (2005), 65(10), 4126-4133
 CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:417568 CAPLUS

DOCUMENT NUMBER: 139:5159

TITLE: **Overexpressed in cancer of huntingtin
 interacting protein, HIP1,
 antibodies, HIP1-encoding nucleic acids, and
 diagnostic and therapeutic uses**

INVENTOR(S): Ross, Theodora; Mizukami, Ikuko; Roa, Dinesh
 PATENT ASSIGNEE(S): The Regents of the University of Michigan, USA
 SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003043566	A2	20030530	WO 2002-US36175	20021112
WO 2003043566	A3	20050303		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003124533 A1 20030703 US 2001-7047 20011206
 CA 2467459 AA 20030530 CA 2002-2467459 20021112
 AU 2002359381 A1 20030610 AU 2002-359381 20021112
 EP 1527190 A2 20050504 EP 2002-793914 20021112

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

US 2004265929 A1 20041230 US 2004-767325 20040129
 WO 2005072457 A2 20050811 WO 2005-US3330 20050128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-335276P	P	20011115
US 2001-7047	A	20011206
WO 2002-US36175	W	20021112
US 2004-767325	A	20040129

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1993:557906 CAPLUS
 DOCUMENT NUMBER: 119:157906
 TITLE: The comparative study on binding sites of McAb-
HIP1, HIP2, HIP7, APT4; and Sj-9A4 on platelet
 surface membrane

AUTHOR(S): Liu, Jiewen; Wang, Meijian; et al.
 CORPORATE SOURCE: Inst. Hematol., CAMS, Tianjin, 300020, Peop. Rep.
 China
 SOURCE: Zhonghua Xueyexue Zazhi (1993), 14(3), 118-20
 CODEN: CHTCD7; ISSN: 0253-2727
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1991:511356 CAPLUS
 DOCUMENT NUMBER: 115:111356
 TITLE: Changes of cytosolic calcium concentration in
 fura-2-loaded human platelets induced by monoclonal
 antibodies HIP2, APT4, HI117 and SJ-9A4

AUTHOR(S): Wang, Meijian; Yu, Aixin; Li, Jiazeng
 CORPORATE SOURCE: Inst. Hematol., Chin. Acad. Med. Sci., Tianjin, Peop.
 Rep. China
 SOURCE: Zhonghua Xueyexue Zazhi (1991), 12(2), 58-60, 110
 CODEN: CHTCD7; ISSN: 0253-2727
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

=> file pctfull
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
26.93	27.14

FILE LAST UPDATED: 23 MAY 2006 <20060523/UP>
MOST RECENT UPDATE WEEK: 200620 <200620/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.

SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
(last updated April 10, 2006) <<<

=> s (huntingtin interacting) or HIP1
490 HUNTINGTIN
6 HUNTINGTINS
491 HUNTINGTIN
(HUNTINGTIN OR HUNTINGTINS)
38966 INTERACTING
132 HUNTINGTIN INTERACTING
(HUNTINGTIN(W) INTERACTING)
37 HIP1
L12 152 (HUNTINGTIN INTERACTING) OR HIP1

=> s antibod?
L13 88064 ANTIBOD?

=> s autoantibod?
L14 2913 AUTOANTIBOD?

=> s l14 or l13
L15 88157 L14 OR L13

=> s serum or sera or blood or urine
88399 SERUM
1418 SERUMS
48167 SERA
120467 SERUM
(SERUM OR SERUMS OR SERA)
48167 SERA
45 SERAS
48182 SERA
(SERA OR SERAS)
131048 BLOOD
285 BLOODS
131061 BLOOD
(BLOOD OR BLOODS)
26898 URINE
426 URINES
27016 URINE
(URINE OR URINES)
L16 190292 SERUM OR SERA OR BLOOD OR URINE

=> s l15 (S) l16
L17 43564 L15 (S) L16

=> s l16 (4W) l16
L18 49900 L16 (4W) L16

=> s l16 (4W) l15
L19 10830 L16 (4W) L15

=> s l19 and l12

L20 13 L19 AND L12

=> s 120 not py>2002
401094 PY>2002
L21 8 L20 NOT PY>2002

=> d ibib 1-4

L21 ANSWER 1 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2002094864 PCTFULL ED 20021210 EW 200248
TITLE (ENGLISH): HUMAN CDNAS AND PROTEINS AND USES THEREOF
TITLE (FRENCH): ADNC ET PROTEINES HUMAINES, AINSI QUE LEURS
UTILISATIONS
INVENTOR(S): BEJANIN, Stephane, 35, boulevard Rochechouart, F-75009
Paris, FR [FR, FR];
TANAKA, Hiroaki, 8, avenue de la Providence, F-92160
Antony, FR [FR, FR]
PATENT ASSIGNEE(S): GENSET, Intellectual Property Department, 24, rue
Royale, F-75008 Paris, FR [FR, FR], for all designates
States except US;
BEJANIN, Stephane, 35, boulevard Rochechouart, F-75009
Paris, FR [FR, FR], for US only;
TANAKA, Hiroaki, 8, avenue de la Providence, F-92160
Antony, FR [FR, FR], for US only
AGENT: GENSET\$, Intellectual Property Department, 24, rue
Royale, F-75008 Paris\$, FR
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002094864	A2	20021128

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-IB1715 A 20010806

PRIORITY INFO.:

US 2001-60/293,574 20010525
US 2001-60/298,698 20010615
US 2001-60/302,277 20010629
US 2001-60/305,456 20010713

L21 ANSWER 2 OF 8

PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2002060934 PCTFULL ED 20020815 EW 200232
TITLE (ENGLISH): IDENTIFICATION OF THE ANTI- σ FACTOR IN
HELICOBACTER PYLORI, IN CAMPYLOBACTER JEJUNI AND IN
PSEUDOMONAS AERUGINOSA AND APPLICATION THEREOF
TITLE (FRENCH): IDENTIFICATION DU FACTEUR ANTI- σ CHEZ
HELICOBACTER PYLORI, CAMPYLOBACTER JEJUNI ET
PSEUDOMONAS AERUGINOSA ET APPLICATION DE CELUI-CI
INVENTOR(S): LEGRAIN, Pierre, 5, rue Mizon, F-75015 Paris, FR [FR,
FR];
COLLAND, Frederic, 12, avenue de Haute Greve, F-95470
Fosses, FR [FR, FR];
RAIN, Jean-Christophe, 32, Jardins Boieldieu, F-92800
Puteaux, FR [FR, FR];

LABIGNE, Agnes, 47, avenue Beausejour, F-91440
Bures-sur-Yvette, FR [FR, FR];
DE REUSE, Hilde, 49, rue Rouelle, F-75015 Paris, FR
[FR, FR]
PATENT ASSIGNEE(S): HYBRIGENICS, 3-5 Impasse Reille, F-75014 Paris, FR [FR,
FR], for all designates States except US;
INSTITUT PASTEUR, 25-28, rue du Dr. Roux, F-75724 Paris
Cedex 15, FR [FR, FR], for all designates States except
US;
LEGRAIN, Pierre, 5, rue Mizon, F-75015 Paris, FR [FR,
FR], for US only;
COLLAND, Frederic, 12, avenue de Haute Greve, F-95470
Fosses, FR [FR, FR], for US only;
RAIN, Jean-Christophe, 32, Jardins Boieldieu, F-92800
Puteaux, FR [FR, FR], for US only;
LABIGNE, Agnes, 47, avenue Beausejour, F-91440
Bures-sur-Yvette, FR [FR, FR], for US only;
DE REUSE, Hilde, 49, rue Rouelle, F-75015 Paris, FR
[FR, FR], for US only
AGENT: DESAIX, Anne\$, Ernest Gutmann-Yves Plasseraud S.A., 3,
rue Chauveau-Lagarde, F-75008 Paris\$, FR
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002060934	A2	20020808
DESIGNATED STATES			
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW		
RW (ARIPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-EP1625	A	20020128
PRIORITY INFO.:	US 2001-60/265,465		20010131
L21 ANSWER 3 OF 8	PCTFULL COPYRIGHT 2006 Univentio on STN		
ACCESSION NUMBER:	2002036741 PCTFULL ED 20020523 EW 200219		
TITLE (ENGLISH):	POLYNUCLEOTIDE ENCODING AN ACTIVATED HUMAN T-LYMPHOCYTE-DERIVED PROTEIN RELATED TO UBIQUITIN CONJUGATING ENZYME		
TITLE (FRENCH):	POLYNUCLEOTIDE CODANT POUR UNE PROTEINE DERIVEE D'UN LYMPHOCYTE T HUMAIN ACTIVE LIEE A UNE ENZYME SE CONJUGUANT A L'UBIQUITINE		
INVENTOR(S):	BOWEN, Michael, A., 7812 Polara Place, Rockville, MD 20855, US; WU, Yuli, 3 Susanna Way, Newtown, PA 18940, US; YANG, Wen-Ping, 25 Rutgers Lane, Princeton, NJ 08540, US; FINGER, Joshua, N., Apartment 254, 22 Woodland Parkway, San Marcos, CA 92069, US		
PATENT ASSIGNEE(S):	BRISTOL-MYERS SQUIBB COMPANY, P.O. Box 4000, Lawrenceville-Provinceline Road, Princeton, NJ 08543-4000, US [US, US]		
AGENT:	KLEIN, Christopher, A.\$, Bristol-Myers Squibb Company, P.O. Box 4000, Lawrenceville-Provinceline Road, Princeton, NJ 08543-4000\$, US		
LANGUAGE OF FILING:	English		

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER KIND DATE

WO 2002036741 A2 20020510

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK
SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-US46559 A 20011029

PRIORITY INFO.:

US 2000-60/244,688 20001030

US 2001-60/308,706 20010730

L21 ANSWER 4 OF 8

PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER:

2002006317 PCTFULL ED 20020814

TITLE (ENGLISH):

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS
OF OVARIAN CANCER

TITLE (FRENCH):

COMPOSITIONS ET PROCEDES UTILISES DANS LA THERAPIE ET
LE DIAGNOSTIC DU CANCER DES OVAIRES

INVENTOR(S):

MITCHAM, Jennifer, L.;
KING, Gordon, E.;
ALGATE, Paul, A.;
FLING, Steven, P.;
RETTTER, Marc, W.;
FANGER, Gary, Richard;
REED, Steven, G.;
VEDVICK, Thomas, S.;
CARTER, Darrick;
HILL, Paul;
ALBONE, Earl

PATENT ASSIGNEE(S):

CORIXA CORPORATION;
MITCHAM, Jennifer, L.;
KING, Gordon, E.;
ALGATE, Paul, A.;
FLING, Steven, P.;
RETTTER, Marc, W.;
FANGER, Gary, Richard;
REED, Steven, G.;
VEDVICK, Thomas, S.;
CARTER, Darrick;
HILL, Paul;
ALBONE, Earl

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER KIND DATE

WO 2002006317 A2 20020124

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW
MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF
BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-US22635	A 20010717
PRIORITY INFO.:	US 2000-09/617,747	20000717
	US 2000-09/636,801	20000810
	US 2000-09/667,857	20000920
	US 2001-09/827,271	20010404
	US 2001-09/884,441	20010618

=> d kwic 4

L21 ANSWER 4 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . Laboratory Manual, Cold Spring Harbor
 Laboratory, 1988. For example, a polypeptide may be immobilized on a
 solid support
 and contacted with patient **sera** to allow binding of
antibodies within the sera to the
 immobilized polypeptide. Unbound sera may then be removed and bound
 antibodies
 detected using, for example, 125 I-labeled. . .
 . . .
 RalGDS-like 2 (RGL2)
 21555 (SEQ ID NO:342) human autoantigen P542
 21548 (SEQ ID NO:343) human actin-related protein (ARP2)
 21462 (SEQ ID NO:344) human **huntingtin interacting**
 protein
 21441 (SEQ ID NO:345) human 90K product (tumor associated antigen)
 21439 (SEQ ID NO:346) human guanine nucleotide regulator protein (tim I)
 21438. . .

=> s prosta?

L22 38449 PROSTA?

=> s l22 and l21

L23 6 L22 AND L21

=> d ibib 1-6

L23 ANSWER 1 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2002094864 PCTFULL ED 20021210 EW 200248
 TITLE (ENGLISH): HUMAN CDNAS AND PROTEINS AND USES THEREOF
 TITLE (FRENCH): ADNC ET PROTEINES HUMAINES, AINSI QUE LEURS
 UTILISATIONS
 INVENTOR(S): BEJANIN, Stephane, 35, boulevard Rochechouart, F-75009
 Paris, FR [FR, FR];
 TANAKA, Hiroaki, 8, avenue de la Providence, F-92160
 Antony, FR [FR, FR]
 PATENT ASSIGNEE(S): GENSET, Intellectual Property Department, 24, rue
 Royale, F-75008 Paris, FR [FR, FR], for all designates
 States except US;
 BEJANIN, Stephane, 35, boulevard Rochechouart, F-75009
 Paris, FR [FR, FR], for US only;
 TANAKA, Hiroaki, 8, avenue de la Providence, F-92160
 Antony, FR [FR, FR], for US only
 AGENT: GENSET\$, Intellectual Property Department, 24, rue
 Royale, F-75008 Paris\$, FR
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2002094864	A2	20021128

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
 TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-IB1715 A 20010806

PRIORITY INFO.:

US 2001-60/293,574 20010525

US 2001-60/298,698 20010615

US 2001-60/302,277 20010629

US 2001-60/305,456 20010713

L23 ANSWER 2 OF 6

ACCESSION NUMBER:

PCTFULL COPYRIGHT 2006 Univentio on STN

TITLE (ENGLISH):

2002036741 PCTFULL ED 20020523 EW 200219

POLYNUCLEOTIDE ENCODING AN ACTIVATED HUMAN
 T-LYMPHOCYTE-DERIVED PROTEIN RELATED TO UBIQUITIN
 CONJUGATING ENZYME

TITLE (FRENCH):

POLYNUCLEOTIDE CODANT POUR UNE PROTEINE DERIVEE D'UN
 LYMPHOCYTE T HUMAIN ACTIVE LIEE A UNE ENZYME SE
 CONJUGUANT A L'UBIQUITINE

INVENTOR(S):

BOWEN, Michael, A., 7812 Polara Place, Rockville, MD
 20855, US;

WU, Yuli, 3 Susanna Way, Newtown, PA 18940, US;

YANG, Wen-Ping, 25 Rutgers Lane, Princeton, NJ 08540,
 US;

FINGER, Joshua, N., Apartment 254, 22 Woodland Parkway,
 San Marcos, CA 92069, US

PATENT ASSIGNEE(S):

BRISTOL-MYERS SQUIBB COMPANY, P.O. Box 4000,
 Lawrenceville-Provinceline Road, Princeton, NJ
 08543-4000, US [US, US]

AGENT:

KLEIN, Christopher, A.\$, Bristol-Myers Squibb Company,
 P.O. Box 4000, Lawrenceville-Provinceline Road,
 Princeton, NJ 08543-4000\$, US

LANGUAGE OF FILING:

English

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002036741	A2	20020510

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK
 SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-US46559 A 20011029

PRIORITY INFO.:

US 2000-60/244,688 20001030

US 2001-60/308,706 20010730

L23 ANSWER 3 OF 6

ACCESSION NUMBER:

PCTFULL COPYRIGHT 2006 Univentio on STN

2002006317 PCTFULL ED 20020814

TITLE (ENGLISH):

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS
 OF OVARIAN CANCER

TITLE (FRENCH): COMPOSITIONS ET PROCEDES UTILISES DANS LA THERAPIE ET
 LE DIAGNOSTIC DU CANCER DES OVAIRES
 INVENTOR(S): MITCHAM, Jennifer, L.;
 KING, Gordon, E.;
 ALGATE, Paul, A.;
 FLING, Steven, P.;
 RETTER, Marc, W.;
 FANGER, Gary, Richard;
 REED, Steven, G.;
 VEDVICK, Thomas, S.;
 CARTER, Darrick;
 HILL, Paul;
 ALBONE, Earl
 PATENT ASSIGNEE(S): CORIXA CORPORATION;
 MITCHAM, Jennifer, L.;
 KING, Gordon, E.;
 ALGATE, Paul, A.;
 FLING, Steven, P.;
 RETTER, Marc, W.;
 FANGER, Gary, Richard;
 REED, Steven, G.;
 VEDVICK, Thomas, S.;
 CARTER, Darrick;
 HILL, Paul;
 ALBONE, Earl
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002006317	A2	20020124

DESIGNATED STATES
 W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
 TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW
 MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
 CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF
 BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US22635 A 20010717
 PRIORITY INFO.: US 2000-09/617,747 20000717
 US 2000-09/636,801 20000810
 US 2000-09/667,857 20000920
 US 2001-09/827,271 20010404
 US 2001-09/884,441 20010618

L23 ANSWER 4 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2000076531 PCTFULL ED 20020515
 TITLE (ENGLISH): 47 HUMAN SECRETED PROTEINS
 TITLE (FRENCH): 47 PROTEINES HUMAINES SECRETEES
 INVENTOR(S): ROSEN, Craig, A.;
 RUBEN, Steven, M.;
 KOMATSOULIS, George, A.RP : HOOVER, Kenley, K.
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;
 ROSEN, Craig, A.;
 RUBEN, Steven, M.;
 KOMATSOULIS, George, A.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000076531	A1	20001221

DESIGNATED STATES

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG
ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI
FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN
GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US15137 A 20000601
PRIORITY INFO.: US 1999-60/138,625 19990611

L23 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2000018916 PCTFULL ED 20020515
TITLE (ENGLISH): HUMAN GENES AND GENE EXPRESSION PRODUCTS
TITLE (FRENCH): GENES HUMAINS ET PRODUITS D'EXPRESSION GENIQUE
INVENTOR(S): WILLIAMS, Lewis, T.;

ESCOBEDO, Jaime;
INNIS, Michael, A.;
GARCIA, Pablo, Dominguez;
SUDDUTH-KLINGER, Julie;
REINHARD, Christoph;
GIESE, Klaus;
RANDAZZO, Filippo;
KENNEDY, Giulia, C.;
POT, David;
KASSAM, Altaf;
LAMSON, George;
DRMANAC, Radoje;
CRKVENJAKOV, Radomir;
DICKSON, Mark;
DRMANAC, Snezana;
LABAT, Ivan;
LESHKOWITZ, Dena;
KITA, David;
GARCIA, Veronica;
JONES, Lee, William;
STACHE-CRAIN, Birgit

PATENT ASSIGNEE(S): CHIRON CORPORATION;
HYSEQ INC.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000018916	A2	20000406

DESIGNATED STATES

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO
NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ
VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY
KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE
IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE
SN TD TG

APPLICATION INFO.: WO 1999-US22226 A 19990923
PRIORITY INFO.: US 1998-60/102,161 19980928
US 1998-60/102,180 19980928
US 1998-60/102,380 19980929
US 1998-60/103,815 19981008
US 1998-60/105,877 19981027

L23 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1999038972 PCTFULL ED 20020515
TITLE (ENGLISH): HUMAN GENES AND GENE EXPRESSION PRODUCTS II

TITLE (FRENCH):	GENES HUMAINS ET PRODUITS II D'EXPRESSION GENIQUE		
INVENTOR(S):	WILLIAMS, Lewis, T.; ESCOBEDO, Jaime; INNIS, Michael, A.; GARCIA, Pablo, Dominguez; SUDDUTH-KLINGER, Julie; REINHARD, Christoph; GIESE, Klaus; RANDAZZO, Filippo; KENNEDY, Giulia, C.; POT, David; KASSAM, Altaf; LAMSON, George; DRMANAC, Radoje; CRKVENJAKOV, Radomir; DICKSON, Mark; DRMANAC, Snezana; LABAT, Ivan; LESHKOWITZ, Dena; KITA, David; GARCIA, Veronica; JONES, Lee, William; STACHE-CRAIN, Birgit		
PATENT ASSIGNEE(S):	CHIRON CORPORATION; HYSEQ INC.; WILLIAMS, Lewis, T.; ESCOBEDO, Jaime; INNIS, Michael, A.; GARCIA, Pablo, Dominguez; SUDDUTH-KLINGER, Julie; REINHARD, Christoph; GIESE, Klaus; RANDAZZO, Filippo; KENNEDY, Giulia, C.; POT, David; KASSAM, Altaf; LAMSON, George; DRMANAC, Radoje; CRKVENJAKOV, Radomir; DICKSON, Mark; DRMANAC, Snezana; LABAT, Ivan; LESHKOWITZ, Dena; KITA, David; GARCIA, Veronica; JONES, Lee, William; STACHE-CRAIN, Birgit		
LANGUAGE OF PUBL.:	English		
DOCUMENT TYPE:	Patent		
PATENT INFORMATION:			
	NUMBER	KIND	DATE

	WO 9938972	A2	19990805
DESIGNATED STATES			
W:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1999-US1619	A	19990128
PRIORITY INFO.:	US 1998-60/072,910		19980128
	US 1998-60/075,954		19980224

US 1998-60/080,114	19980331
US 1998-60/080,515	19980403
US 1998-60/080,666	19980403

=> d kwic 3

L23 ANSWER 3 OF 6 PCTFULL COPYRIGHT 2006 Univention on STN

DETD . . . Laboratory Manual, Cold Spring Harbor
Laboratory, 1988. For example, a polypeptide may be immobilized on a
solid support
and contacted with patient **sera** to allow binding of
antibodies within the sera to the
immobilized polypeptide. Unbound sera may then be removed and bound
antibodies
detected using, for example, 125 I-labeled. . . .

. . .
RalGDS-like 2 (RGL2)
21555 (SEQ ID NO:342) human autoantigen P542
21548 (SEQ ID NO:343) human actin-related protein (ARP2)
21462 (SEQ ID NO:344) human **huntingtin interacting**
protein
21441 (SEQ ID NO:345) human 90K product (tumor associated antigen)
21439 (SEQ ID NO:346) human guanine nucleotide regulator protein (tim I)
21438. . .

For generation of polyclonal anti-sera, 400 micrograms of each
prostate
antigen was combined with 100 micrograms'of muramyldipeptide (MDP).
Equal
volume of Incomplete Freund's Adjuvant (IFA) was added and then mixed.
Every four
weeks. . . .

=> d kwic 6

L23 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univention on STN

[illegible]

=> d kwic 5

L23 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . can be assayed in body fluids that are convenient, such as blood, plasma, serum, and other body fluids such as urine, **prostatic** fluid and semen. Membrane-bound polypeptides are useful for constructing vaccine antigens or inducing an immune response. Such antigens would comprise all or. . .

The invention also contemplates naturally occurring antibodies specific for a polypeptide of the invention. For example, **serum antibodies** to a polypeptide of the invention in a human population can be purified by methods well known in the art, . . .

. . . sample, or any normal tissue of the patient, especially those that express the polynucleotide-related gene of interest (e.g., brain, thymus, testis, heart, **prostate**, placenta, spleen, small intestine, skeletal muscle, pancreas, and the mucosal lining of the colon). A difference between the polynucleotide-related gene, mRNA, . . .

3 5 Detection of **prostate** cancer. The polynucleotides and their corresponding genes and gene

3 8

products exhibiting the appropriate differential expression pattern can be used to detect **prostate** cancer in a subject. Over 95% of primary **prostate** cancers are adenocarcinomas. Signs and symptoms may include: frequent urination, especially at night, inability to urinate, trouble starting or holding back urination, . . .

Many of the signs and symptoms of **prostate** cancer can be caused by a variety of other non-cancerous conditions. For example, one common cause of many of these signs and symptoms is a condition called benign **prostatic** hypertrophy, or BPH. In BPH, the **prostate** gets bigger and may block the flow of urine or interfere with sexual function. The methods and compositions of the invention can be used to distinguish between **prostate** cancer and such non-cancerous conditions.

. . . invention can be used in conjunction with conventional methods of diagnosis, e.g., digital rectal exam and/or detection of the level of **prostate** specific antigen (PSA), a substance produced and secreted by the **prostate**.

. . . gland double-headed protease inhibitors, which contain two Kazal-type domains, the first one inhibits trypsin and the second one elastase. a mouse **prostatic** secretory glycoprotein, induced by androgens, and which exhibits anti-trypsin activity-, avian ovomucoids; chicken ovomucoid; and the leech trypsin inhibitor Bdegin B The. . .

. . . cDNA library)
20 Liver Metastasis from Colon Tumor of UC#3 Patient 30956

(MICRODISSECTED PCR (OligodT) cDNA library)
 21 GRRpz Cells derived from normal **prostate** epithelium 164801
 22 WOca Cells derived from Gleason Grade 4 **prostate** 162088
 cancer epithelium
 23 Normal Lung Epithelium of Patient # 1 006 306198
 (MICRODISSECTED PCR (OligodT) cDNA library)
 Primary tumor, Large Cell Carcinoma of. . .

Donna M. Peehl, Department of Medicine, Stanford University School of
 Medicine. GRRpz was
 derived from normal **prostate** epithelium. The WOca cell line is
 a Gleason Grade 4 cell line.

. . .
 genome IE-35
 490 JAB016492.1 Homo sapiens hJTB gene, complete cds e-I 18
 491 X98176 H.sapiens mRNA for MACH-beta- I protein IE-36
 Homo sapiens **huntingtin interacting** protein HYPK
 mRNA,
 492 AF049613 partial cds 7E-22
 493 AF039690.1, Homosapiens antigen NY-CO-8 (NY-CO-8) mRNA, partial cds IE-37
 INM-001003I Homo sapiens ribosomal protein, large, PI ribosomal
 494 phosphoprotein PI mRNA, complete cds.. . .

. . .
 of 3] 1.9
 5 Homo sapiens retinal pigment epithelium-specific protein
 588 AF039857 (RPE65) gene, exon 3 0.023
 589 X05034 Rat C2A gene for **prostatic** binding protein (PBP)
 0.2
 Rattus norvegicus clone ubc4a ubiquitin conjugating enzyme
 590 U13177 (E217kB) rnRNA, complete cds. 0.071
 591 AF081530 Homo sapiens neuralized. . .

. . .
 beta-globin mRNA, 5'UTR. 0.03
 Haemophilus influenzae Rd section 107 of 163 of the complete
 684 U32792 genome 2.1
 685 X74969 R.norvegicus gene for **prostatic** acid phosphatase
 0.02
 Phanerochaete chrysosporium manganese peroxidase isozyme 3
 686 U70998 (mnp3) gene, complete cds 0.73
 Homo sapiens nucleosome assembly protein I-like 4. . .

=> d kwic 4

L23 ANSWER 4 OF 6 PCTFULL COPYRIGHT 2006 Univention on STN

DETD . . . cells-treated with estradiol; Smooth muscle, IL1b induced;
 Synovial hypoxia-
 RSF subtracted; Human Whole Brain #2 - Oligo dT > 1.5Kb; LNCAP
prostate cell
 line; HL-60, PMA 4H, re-excision; Synovial hypoxia; Jurkat T-cell GI
 phase; Brain
 Frontal Cortex, re-excision; Human Umbilical Vein, Reexcision; HUMAN
 JURKAT
 MEMBRANE. . .
 . . .
 (10 nM 132) fraction 1; Activated T-cells; Human T-cell
 lymphoma, re-excision; Soares retina N2b4HR; STRONIAL -OSTEOCLASTOMA;
 Soares pregnant uterus NbHPU; Synovial hypoxia-RSF subtracted;
Prostate BPH;
 NCI CGAP Co3; NCI CGAP-GCB 1; Monocyte activated, re-excision; Human
 Pancreas Tumor, Reexcision; Olfactory epithelium, nasalcavity; Human
 Placenta (re-
 excision); Human Activated T-Cells, re-excision; Ulcerative Colitis;. .

. Synovial IL-
 I/TNF stimulated; Human endometrial stromal cells-treated with
 progesterone;
 Human Osteoclastoma, re-excision; Human Adult Small Intestine; Human
 Neutrophil; Human Chronic Synovitis; Human **Prostate**; Human
 Thymus;
 NCI-CGAP-Br3; NCI_CGAP-co8; NCI_CGAP-co9; NCI_CGAP-Kid3;
 NCI-CGAP-Larl; NCI_CGAP-Prl 1; 12 Week Old Early Stage Human, 11; HUMAN
 JURKAT MEMBRANE BOUND POLYSOMES; T-Cell PHA. . .

gil3341980 (all information available through the recited accession
 number is
 incorporated herein by reference) which is described therein as
huntingtin-interacting
 protein HYPA/FBPI I ['Homo sapiens]. A partial alignment demonstrating
 the
 observed homology is shown immediately below.

>gil3341980 (AF049523) **huntingtin-interacting**
 protein HYPA/FBP11 [Homo
 sapiens]
 >SP10754001075400 **HUNTINGTIN-INTERACTING** PROTEIN
 HYPA/FBP11
 (FRAGMENT). >gil3341982 (AF049524) **huntingtin-**
interacting
 protein
 HYPA/FBP11 [Homo sapiens] fSUB 17-1831 >giII255025 FBP 11 [Mus
 musculus] fSUB 121-1871
 Length = 423
 Plus Strand HSPs.

.
 .
 .
 Synovial Fibroblasts (control); Soares breast 3NbHBst; NCI CGAP CA
 Jurkat Cells, cyclohexamide treated, subtraction; NCI_CGAP-GC4;
 NCI-CGAP-GCB I; NCI-CGAP-Brn23; Soares-testis_NHT;
 Soares-total-fetus-Nb2HF8-9w; Human Lung; Soares-pregnant-Uterus-NbHPU;
 Human **Prostate** Cancer, Stage C fraction; NTERA2 + retinoic
 acid, 14 days; Salivary
 Gland, Lib 2; Stratagene endothelial cell 937223; Human Umbilical Vein,
 Reexcision;. . . (#937210); Human Liver,
 normal; Soares-pregnant-uterus-NbHPU; Pancreatic Islet;
 Soares-placenta-8to9weeks-2NbHP8to9W; Primary Dendritic cells,frac 2;
 NCI-CGAP-GCB 1; T cell helper 11; Soares fetal liver spleen I NFLS;
Prostate/LNCAP, subtraction 1; Human Umbilical Vein
 Endothelial Cells, fract. B;
 Whole brain; Human Tongue, frac 1; Clontech human aorta polyA+ mRNA
 (#6572);
 Human. . . Human Amygdala, re-excision; Human Osteoclastoma, re-
 excision; Stratagene ovarian cancer (#937219); Human endometrial stromal
 cells;
 Human Manic Depression Tissue; Spleen metastatic melanoma; Human
Prostate;
 KMH2; Human Thymus; Apoptotic T-cell; HUMAN JURKAT MEMBRANE
 BOUND POLYSOMES; Human Heart; Human Ovary; Rejected Kidney, lib 4;
 CHME Cell Line, treated 5 hrs;. . .

.
 .
 .
 cell line, remake; HSC172 cells; Supt
 Cells, cyclohexamide treated; Activated T-Cells, 12 hrs, re-excision;
 Mesangial cell,
 frac 2; Human Epididymus; Stratagene placenta (#937225); LNCAP
prostate cell line;
 Human Osteosarcoma; Human Colon, re-excision; H. Kidney Medulla,
 re-excision;
 Human Bone Marrow, re-excision; Human Fetal Kidney; Human Umbilical Vein
 Endothelial Cells,. . .

Heart, re-excision; Human adult small intestine, re-excision; Human Lung Cancer, re-excision; Apoptotic T-cell, re-excision; Soares-pineal-gland_N3HPG; HEL cell line; Stomach cancer (human), re-excision; Human Colon Cancer, re-excision; STROMAL -OSTEOCLASTOMA; Human **Prostate** Cancer, Stage C fraction; pBMC stimulated w/ poly I/C; Alzheimers, spongy change; Human Umbilical Vein, Endo. remake; Synovial hypoxia-RSF subtracted; Human Stomach, re-excision; . . .

fetal spleen (#937205); Human Adult Testes, Large Inserts, Reexcision; Hemangiopericytoma; Pancreas Islet Cell Tumor; NCI_CGAP-GCB I; Soares-parathyroid-tumor-NbHPA; normalized infant brain cDNA; PC3 **Prostate** cell line; Human Synovial Sarcoma; Endothelial-induced; Keratinocyte; Soares-fetal-heart-NbHH19W; Larynx Normal; H. Frontal Cortex, Epileptic; Soares I -pineal gland N3HPG; H Umbilical Vein Endothelial Cells, . . .

Activated T-Cells, re-excision; NCI_CGAP-Kid3; NCI-CGAP-Brn25; Human Testes Tumor, re-excision; CHME Cell Line, treated 5 hrs; Hepatocellular Tumor, re-excision; Pancreas Islet Cell Tumor; PC3 **Prostate** cell line; Colon Tumor; Smooth muscle, serum treated; Human Placenta; NCI_CGAP-Br2; NCI-CGAP-GC4; NCI_CGAP-Kid3; NCI_CGAP-Kid6; NCI_CGAP_PrI2; Colon Tumor 11; Human Synovial Sarcoma; Human fetal. . .

Human skeletal muscle cDNA library, cat. #936215.; Soares-testis-NHT; Stratagene lung carcinoma 937218; Subtracted human retinal pigment epithelium (RPE); Spleen/normal; Colon Normal; Human **Prostate**, subtracted; Human epithelioid sarcoma; stomach cancer (human); HUMAN STOMACH; Activated T-cells; Human Thyroid; Human Lung; Human Epididymus; Human Hypothalamus, schizophrenia, re-excision; Human Osteosarcoma; Synovial Fibroblasts (11 I/TNF), subt; Human Manic Depression Tissue; Spleen metastatic melanoma; Human Adult Small Intestine; Human Neutrophil; Human **Prostate**; 12 Week Old Early Stage Human, 11; Human Umbilical Vein Endothelial Cells, uninduced; Human Fetal Dura Mater; Liver, Hepatoma; Ulcerative Colitis; Human Fetal. . .

A; Monocyte activated; Human Bone Marrow, treated; Hodgkin's Lymphoma 11; Morton Fetal Cochlea; H. Striatum Depression, subt; HUMAN STOMACH; Human Epididymus; Human **Prostate** Cancer, Stage C fraction; Human Osteoclastoma, re-excision; Human **Prostate**; T-Cell PHA 16 hrs; Human colorectal cancer; Soares-NhHMPu_S I; Temporal cortex-Alzheimer, subtracted; Monocyte activated, re-excision; Stratagene fetal spleen (#937205); T-Cell PHA 24. . .

hypothalamus, frac A; Human Whole 6 Week Old Embryo (11), subt; Salivary Gland,

Lib 3; LNCAP + 3OnM R1881; Human **Prostate**, subtracted; Saos2
 Cells, Vitamin D3
 Treated; Saos2, Dexamethosome Treated; Human OB HOS treated (1 nM E2)
 fraction 1; Human Colon, subtraction; Human. . .
 .
 i um (#93723 1); Stratagene ovary (#937217); HL-60, PMA 4H, re-
 excision; Jurkat T-cell G I phase; Human Thymus; NCI-CGAP-Co3;
 NCI-CGAP-SSI; PC3 **Prostate** cell line; CHME Cell
 Line, untreated; Soares breast
 3NbHBst; Human Fetal Kidney, Reexcision; Human Synovial Sarcoma;
 Soares-fetal-heart-NbHH19W; Soares-NhHMPu_S I; Bone Marrow Cell Line
 (RS4,1 1); Stratagene HeLa cell s3 937216; Keratinocyte; Soares placenta
 Nb2HP;
 Soares_NhHMPu_S I; Normal **Prostate**; Whole 6 Week Old Embryo;
 Human colon
 carcinoma (HCQ cell line, remake; Human Cerebellum, subtracted; Human
 Placenta;
 H. Epididymus, caput & corpus;. . . retina N2b4HR;
 Soares_NhHMPu_S I; Apoptotic T-cell, re-excision; Stomach cancer
 (human), re-
 excision; NTERA2 + retinoic acid, 14 days; Jurkat T-Cell, S phase;
 wilm's tumor;
Prostate BPH; H. Lymph node breast Cancer; TF- I Cell Line
 GM-CSF Treated;
 Breast Cancer Cell line, anglogenic; Human Fetal Kidney; HUMAN. . .
 .
 Whole Embryo; Soares placenta
 Nb2HP; Salivary gland, re-excision; Human White Fat; Human Colon
 Cancer, re-
 excision; Soares_multiple_sclerosls-2NbHMSP; Salivary Gland, Lib 2;
 Human
 Colon, re-excision; **Prostate** BPH; Human Adult Small Intestine;
 Mo7e Cell Line
 GM-CSF treated (1 ng/ml); Temporal cortex-Alzheimer, subtracted;
 Soares-multiple-sclerosis-2NbHMSP; Human Hypothalamus, Schizophrenia;
 NCI-CGAP-Lu5; NCI_CGAP-Kid3; Olfactory epithelium, nasal cavity; Human
 Adipose;. . .
 .
 extent in Macrophage (GM-CSF treated);
 Soares-senescent-fibroblasts-NbHSF; Human Adult Spleen;
 Adipocytes, re-excision;
 Human Pineal Gland; pBMC stimulated w/ poly I/C; Glioblastoma; Human
 Pituitary,
 subt IX; **Prostate** BPH; T-Cell PHA 24 hrs; Human
 Chondrosarcoma; Soares adult
 brain N2b5HB55Y; Human Adrenal Gland Tumor;
 Soares_NSF_F8_9W_OT_PA_P_S1; Soares-fetal-liver-spleen-INFLS_S1; Smooth
 muscle, serum induced, re-exc; Human Gall. . .
 .
 Adult Small Intestine; Human 8 Week Whole Embryo
 and to a lesser extent in Human Pineal Gland; Kidney medulla; Larynx
 carcinoma IV;
Prostate; Soares retina N2b4HR; Breast Cancer cell line, MDA
 36; Human
 Osteosarcoma; Soares melanocyte 2NbHM; Endothelial cells-control; Human
 brain
 frontal cortex; NCI-CGAP-Lu5; NCI_CGAP-GCB. . .
 .
 Kidney Medulla, re-excision; human ovarian cancer; Stromal cell TF274;
 Human
 Adipose; Human Rhabdomyosarcoma; Soares-NFL-T_GBC_S I; PO
Prostate cell
 line; CHME Cell Line, untreated; Soares
 I -pregnant-uterus_NbHPU; Stratagene

fibroblast (#937212); Colon Tumor 11; Normal colon;
 Soares-multiple-sclerosis-2NbHMSP; Human Fetal Heart; NCI_CGAP-Prl;
 Hodgkin's Lymphoma 11; Human. . . Express; Human
 Macrophage; Human Rejected Kidney, 704 re-excision;
 Soares-total-fetus-Nb2HF8-9w; Colon Normal; Larynx Normal; Human Pre-
 Differentiated Adipocytes; Activated T-Cells, 8 hrs, subtracted; Human
Prostate,
 subtracted; Saos2, Dexamethasone Treated; **prostate**-edited;
 Human Aortic
 Endothelium; SKIN; Human Umbilical Vein Endothelial Cells, fract. A;
 Human fetal
 heart, Lambda ZAP Express; NCI_CGAP Kid3; Adipocytes, re-excision; Smooth
 Muscle Serum Treated, . . . zero hr post-incision (control);
 Pancreas Tumor PCA4 Tu; Human Synovium; Stratagene endothelial cell
 937223;
 Synovial IL-1/TNF stimulated; Smooth muscle, IL1b induced; LNCAP
prostate cell
 line; Human Adipose Tissue, re-excision; Synovial hypoxia; Healing groin
 wound,
 6.5 hours post incision; **Prostate** BPH; Human Adult Small
 Intestine;
 Soares-multiple-sclerosis-2NbHMSP; TF- I Cell Line GM-CSF Treated; Human
 Brain, Striatum; Stratagene fetal spleen (#937205); 12 Week Old. . .
 .
 human ovarian cancer; Human
 Uterine Cancer; Human Placenta (re-excision); Human Chondrosarcoma;
 NTERA2,
 control; Human Gall Bladder; Clontech human aorta polyA+ rRNA (#6572);
 PC3
Prostate cell line; Human Testes Tumor; Colon Tumor 11;
 Dendritic cells, pooled;
 Human Fetal Lung 111; Human Amygdala; NCI_CGAP-Co3; Osteoblasts; Healing
 groin wound, 6.5 hours post incision; H. Meningioma, MI; Human
 Neutrophil; Human
Prostate; Soares_NbHMPu_S 1; KNIH2; Soares-total-fetus-Nb2HF8-
 9w; Human
 Fetal Dura Mater; T-Cell PHA 24 hrs; Human Ovary; Human fetal heart,
 Lambda
 ZAP Express; Rejected Kidney, . . . Human Synovium; Hepatocellular
 Tumor, re-excision; Stratagene placenta (#937225); Synovial. hypoxia-RSF
 subtracted;
 Glioblastoma; Healing groin wound, 7.5 hours post incision; Salivary
 Gland, Lib 2;
 LNCAP **prostate** cell line; Human endometrial stromal cells;
 Soares-pregnant-uterus-NbHPU; **Prostate** BPH; Human Infant
 Brain; Hippocampus,
 Alzheimer Subtracted; H. Kidney Medulla, re-excision; Gessler Wilms
 tumor;
 Soares-fetal-heart-NbHH19W; L428; Human Pancreas Tumor; Human
 Hypothalamus, Schizophrenia; Pancreatic Islet; . . .
 .
 Human Microvascular
 Endothelial Cells, fract. A; Smooth muscle, control; Soares fetal liver
 spleen I NFLS;
 Soares ovary tumor NbHOT; Raji Cells, cyclohexamide treated;
 Glioblastoma;
Prostate BPH; Human Bone Marrow, re-excision; human ovarian
 cancer; Stromal cell
 TF274; Adipocytes; Human Testes Tumor; Keratinocyte; T cell helper 11;
 Cem. . . Nigra;
 Human Adult Pulmonary, re-excision; HUMAN B CELL LYMPHOMA;
 JNCI CGAP GCB I; Human Cerebellum; Whole 6 Week Old Embryo; Human Adult
 Liver, subtracted; **prostate**-edited; LI Cell line; Human Adult
 Spleen; Human Colon;

Human White Adipose; Human Thyroid; Human Lung; Stratagene ovary (#937217);
H. Whole Brain #2, re-excision; Human Umbilical Vein, Endo. remake; Healing
groin wound, 7.5 hours post incision; LNCAP **prostate** cell line; HL-60, PMA 4H, re-excision; Spleen metastatic melanoma; Stratagene ovarian cancer (#937219);
H. Kidney
Medulla, re-excision; CD34 depleted Buffy Coat. . . Fetal Heart; Human
Amygdala; Soares-fetal-liver-spleen_INFLS Sl; Soares-fetal-lung-NbHL19W;
Human Endometrial Tumor; Stratagene fibroblast (#937212); Stratagene endothelial
cell 937223; Human Fetal Brain; HT29M6; Human Myometrium Leiomyoma;
Human **Prostate** Cancer, Stage C; Human Infant Adrenal Gland;
Human Adult Liver;
Activated T-Cells, 8 hrs, differentially expressed; Jurkat Cells, cyclohexamide
treated, subtraction; HeLa. . . subtracted;
Soares-testis-NHT; Soares_NFL-T-GBC-SI; Stratagene hNT neuron (#937233);
Supt cells, cyclohexamide treated, subtracted; Human Gastrocnemius;
Normal
trachea; Bone marrow stroma,treated; Testis, normal; Duodenum; Human
Prostate
Cancer, Stage 132; HPAS (human pancreas, subtracted); Raji cells, cyclohexamide
treated, subtracted; Human B Cell 8866; Human Thymus Tumor, subtracted;
Testes;
Thymus; Human Tonsil, Lib 3; Hypothalamus; Human **Prostate**
Cancer, Stage B2
fraction; H. Normalized Fetal Liver, 11; Human epithelioid sarcoma;
HL-60, RA 4h,
Subtracted; Dermatofibrosarcoma Protuberance; LNCAP untreated; Frontal
Lobe,
Dementia;. . . Cell, untreated; Human Thymus
Stromal Cells; Soares-pregnant-uterus-NbHPU; Fetal Liver, subtraction
11; Ovarian
Tumor 10 95; Pancreas Islet Cell Tumor; NCI-CGAP-Br2; Fetal Heart; PC3
Prostate cell line; Human T-Cell Lymphoma; Human Eosinophils;
breast lymph node
CDNA library; Human Placenta; Human adult (K.Okubo); Human fetal heart,
Lambda ZAP. . .

In another specific embodiment of the present invention, the kit is a diagnostic
kit for use in screening **serum** containing **antibodies**
specific against proliferative
and/or cancerous polynucleotides and polypeptides. Such a kit may
include a control
antibody that does not react with the. . .

. . .
an inflammatory response. These molecules
can be used to treat, prevent, and/or diagnose inflammatory conditions,
both chronic
and acute conditions, including chronic **prostatitis**,
granulomatous **prostatitis** and
malacoplakia, inflammation associated with infection (e.g., septic
shock, sepsis, or
systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion
injury,
endotoxin lethality, arthritis, complement-mediated hyperacute. . .

. . .
which may be treated, prevented, and/or diagnosed with polynucleotides,
polypeptides, antagonists and/or agonists include, but are not limited

to solid tumors,
including **prostate**, lung, breast, ovarian, stomach, pancreas,
larynx, esophagus, testes,
liver, parotid, biliary tract, colon, rectum, cervix, uterus,
endometrium, kidney,
bladder, thyroid cancer; primary. . .

. . .
cancer,
melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer,
testicular
cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma,
endothelioma,
osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma,
breast
cancer, **prostate** cancer, Kaposi's sarcoma and ovarian cancer);
autoimmune diseases,
disorders, and/or conditions (such as, multiple sclerosis, Sjogren's
syndrome,
Hashimoto's thyroiditis, biliary cirrhosis, Behcet's. . .

. . .
myxosarcoma, liposarcoma,
chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,
endotheliosarcoma,
lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma,
Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma,
pancreatic
cancer, breast cancer, ovarian cancer, **prostate** cancer,
squamous cell carcinoma, basal
cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland
carcinoma,
papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma,
medullary
carcinoma, bronchogenic carcinoma,. . .

. . .
example of such methods, cells
expressing a polypeptide of the present invention is administered to an
animal to
induce the production of **sera** containing polyclonal
antibodies. In a preferred
method, a preparation of the secreted protein is prepared and purified
to render it
substantially free of natural contaminants.. . .

. . .
Chapter 2.) As one example of such methods,
cells expressing XXX are administered to an animal to induce the
production of **sera**
1 5 containing polyclonal **antibodies**. In a preferred method, a
preparation of XXX
protein is prepared and purified to render it substantially free of
natural contaminants.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

24.34

51.48

STN INTERNATIONAL LOGOFF AT 13:57:04 ON 30 MAY 2006